Delcath Systems (NASDAQ:DCTH) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Delcath Systems (NASDAQ:DCTH) from a hold rating to a strong-buy rating in a research note released on Monday,Zacks.com reports.

DCTH has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price (up from $30.00) on shares of Delcath Systems in a report on Friday. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday. BTIG Research increased their target price on Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Delcath Systems in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.17.

Delcath Systems Price Performance

NASDAQ:DCTH opened at $17.22 on Monday. The firm has a 50-day moving average of $12.61 and a two-hundred day moving average of $10.97. The stock has a market cap of $597.52 million, a P/E ratio of 1,723.72 and a beta of 0.52. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $17.42.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, August 6th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.16. The company had revenue of $29.13 million during the quarter, compared to analysts’ expectations of $26.25 million. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. As a group, equities analysts expect that Delcath Systems will post -0.17 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

Institutional investors and hedge funds have recently bought and sold shares of the business. Royce & Associates LP acquired a new position in Delcath Systems in the 4th quarter worth approximately $1,566,000. Private Wealth Advisors LLC raised its stake in Delcath Systems by 85.9% during the 4th quarter. Private Wealth Advisors LLC now owns 290,481 shares of the company’s stock valued at $2,934,000 after purchasing an additional 134,198 shares during the period. Leonteq Securities AG purchased a new stake in shares of Delcath Systems in the fourth quarter valued at $293,000. SkyOak Wealth LLC purchased a new stake in shares of Delcath Systems in the fourth quarter valued at $152,000. Finally, State of Alaska Department of Revenue boosted its position in shares of Delcath Systems by 1,194.5% in the fourth quarter. State of Alaska Department of Revenue now owns 26,033 shares of the company’s stock worth $262,000 after buying an additional 24,022 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Key Delcath Systems News

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $32 price target while sharply raising its EPS forecasts. The firm now expects a smaller FY2026 loss of $0.17 per share, versus its prior estimate of $0.88, followed by profitability in FY2027 at $0.12 per share. Longer-term estimates were also increased to $0.56 for FY2028, $0.97 for FY2029 and $1.46 for FY2030, suggesting improved confidence in Delcath’s earnings trajectory. MarketBeat analyst estimates
• Positive Sentiment: Zacks highlighted DCTH as a potential momentum stock, citing favorable price momentum and improving earnings-estimate revisions. Another Zacks analysis said Wall Street analysts see potential upside of approximately 42.8%, although price-target projections are not guaranteed. Zacks momentum stock analysis Zacks price target analysis
• Neutral Sentiment: Reported short interest was zero shares both on August 11 and July 27, producing a zero-day short-interest ratio. Because the report also shows an invalid “NaN” change, the data provides no meaningful indication of short-covering or bearish pressure.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.